-
Je něco špatně v tomto záznamu ?
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
R. Defferrari, K. Mazzocco, IM. Ambros, PF. Ambros, C. Bedwell, K. Beiske, J. Bénard, AP. Berbegall, N. Bown, V. Combaret, J. Couturier, G. Erminio, C. Gambini, A. Garaventa, N. Gross, R. Haupt, J. Kohler, M. Jeison, J. Lunec, B. Marques, T....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1947 do Před 1 rokem
Freely Accessible Journals
od 1947 do Před 1 rokem
PubMed Central
od 1947 do Před 1 rokem
Europe PubMed Central
od 1947 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1947-01-01
Open Access Digital Library
od 1999-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do 2015-11-17
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
PubMed
25356804
DOI
10.1038/bjc.2014.557
Knihovny.cz E-zdroje
- MeSH
- amplifikace genu MeSH
- chromozomální aberace MeSH
- jaderné proteiny genetika MeSH
- Kaplanův-Meierův odhad MeSH
- kojenec MeSH
- lidé MeSH
- nádory periferního nervového systému diagnóza genetika mortalita MeSH
- neuroblastom diagnóza genetika mortalita MeSH
- onkogenní proteiny genetika MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- srovnávací genomová hybridizace MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with localised unresectable neuroblastoma (NB) without MYCN amplification enrolled in the European Unresectable Neuroblastoma (EUNB) protocol is still to be clarified, while, for other group of patients, the presence of SCAs is associated with poor prognosis. METHODS: To understand the role of SCAs we performed multilocus/pangenomic analysis of 98 tumour samples from patients enrolled in the EUNB protocol. RESULTS: Age at diagnosis was categorised into two groups using 18 months as the age cutoff. Significant difference in the presence of SCAs was seen in tumours of patients between 12 and 18 months and over 18 months of age at diagnosis, respectively (P=0.04). A significant correlation (P=0.03) was observed between number of SCAs per tumour and age. Event-free (EFS) and overall survival (OS) were calculated in both age groups, according to both the presence and number of SCAs. In older patients, a poorer survival was associated with the presence of SCAs (EFS=46% vs 75%, P=0.023; OS=66.8% vs 100%, P=0.003). Moreover, OS of older patients inversely correlated with number of SCAs (P=0.002). Finally, SCAs provided additional prognostic information beyond histoprognosis, as their presence was associated with poorer OS in patients over 18 months with unfavourable International Neuroblastoma Pathology Classification (INPC) histopathology (P=0.018). CONCLUSIONS: The presence of SCAs is a negative prognostic marker that impairs outcome of patients over the age of 18 months with localised unresectable NB without MYCN amplification, especially when more than one SCA is present. Moreover, in older patients with unfavourable INPC tumour histoprognosis, the presence of SCAs significantly affects OS.
Center for Medical Genetics Ghent University Hospital Ghent 9000 Belgium
Children's Cancer Research Institute St Anna Kinderkrebsforschung Vienna 1090 Austria
Department of Haematology Oncology Istituto Giannina Gaslini Genova 16148 Italy
Department of Hematology Hospital Universitari i Politècnic La Fe Valencia 46009 Spain
Department of Paediatric Oncology Southampton General Hospital Southampton S016 6YD UK
Department of Pathology Istituto Giannina Gaslini Genova 16148 Italy
Department of Pathology Medical School of Valencia University of Valencia Valencia 46010 Spain
Department of Pathology Oslo University Hospital Rikshopitalet Oslo 0424 Norway
Epidemiology Biostatistics and Committees Unit Istituto Giannina Gaslini Genova 16148 Italy
Laboratoire de Recherche Translationnelle Centre Léon Bérard Lyon 69008 France
Northern Genetics Service Newcastle upon Tyne NEI 3 BZ UK
Northern Institute for Cancer Research Newcastle University Newcastle NE2 4HH UK
Pediatric Oncology Research Unit Lausanne University Hospital Lausanne 1011 Switzerland
Unité de Génétique Somatique et Cytogénétique Institut Curie Paris Cedex 05 75248 France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014015
- 003
- CZ-PrNML
- 005
- 20150424103638.0
- 007
- ta
- 008
- 150420s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/bjc.2014.557 $2 doi
- 035 __
- $a (PubMed)25356804
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Defferrari, R $u Department of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy.
- 245 10
- $a Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification / $c R. Defferrari, K. Mazzocco, IM. Ambros, PF. Ambros, C. Bedwell, K. Beiske, J. Bénard, AP. Berbegall, N. Bown, V. Combaret, J. Couturier, G. Erminio, C. Gambini, A. Garaventa, N. Gross, R. Haupt, J. Kohler, M. Jeison, J. Lunec, B. Marques, T. Martinsson, R. Noguera, S. Parodi, G. Schleiermacher, DA. Tweddle, A. Valent, N. Van Roy, A. Vicha, E. Villamon, GP. Tonini,
- 520 9_
- $a BACKGROUND: The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with localised unresectable neuroblastoma (NB) without MYCN amplification enrolled in the European Unresectable Neuroblastoma (EUNB) protocol is still to be clarified, while, for other group of patients, the presence of SCAs is associated with poor prognosis. METHODS: To understand the role of SCAs we performed multilocus/pangenomic analysis of 98 tumour samples from patients enrolled in the EUNB protocol. RESULTS: Age at diagnosis was categorised into two groups using 18 months as the age cutoff. Significant difference in the presence of SCAs was seen in tumours of patients between 12 and 18 months and over 18 months of age at diagnosis, respectively (P=0.04). A significant correlation (P=0.03) was observed between number of SCAs per tumour and age. Event-free (EFS) and overall survival (OS) were calculated in both age groups, according to both the presence and number of SCAs. In older patients, a poorer survival was associated with the presence of SCAs (EFS=46% vs 75%, P=0.023; OS=66.8% vs 100%, P=0.003). Moreover, OS of older patients inversely correlated with number of SCAs (P=0.002). Finally, SCAs provided additional prognostic information beyond histoprognosis, as their presence was associated with poorer OS in patients over 18 months with unfavourable International Neuroblastoma Pathology Classification (INPC) histopathology (P=0.018). CONCLUSIONS: The presence of SCAs is a negative prognostic marker that impairs outcome of patients over the age of 18 months with localised unresectable NB without MYCN amplification, especially when more than one SCA is present. Moreover, in older patients with unfavourable INPC tumour histoprognosis, the presence of SCAs significantly affects OS.
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 _2
- $a srovnávací genomová hybridizace $7 D055028
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a amplifikace genu $7 D005784
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a neuroblastom $x diagnóza $x genetika $x mortalita $7 D009447
- 650 _2
- $a jaderné proteiny $x genetika $7 D009687
- 650 _2
- $a onkogenní proteiny $x genetika $7 D015513
- 650 _2
- $a nádory periferního nervového systému $x diagnóza $x genetika $x mortalita $7 D010524
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mazzocco, K $u Department of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy.
- 700 1_
- $a Ambros, I M $u Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna 1090, Austria. $7 gn_A_00005353
- 700 1_
- $a Ambros, P F $u Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna 1090, Austria. $7 gn_A_00005356
- 700 1_
- $a Bedwell, C $u Northern Genetics Service, Newcastle upon Tyne NEI 3 BZ, UK.
- 700 1_
- $a Beiske, K $u Department of Pathology, Oslo University Hospital Rikshopitalet, Oslo 0424, Norway.
- 700 1_
- $a Bénard, J $u Département de Biologie et de Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif 94800, France.
- 700 1_
- $a Berbegall, A P $u Department of Pathology, Medical School of Valencia, University of Valencia, Valencia 46010, Spain.
- 700 1_
- $a Bown, N $u Northern Genetics Service, Newcastle upon Tyne NEI 3 BZ, UK.
- 700 1_
- $a Combaret, V $u Laboratoire de Recherche Translationnelle, Centre Léon-Bérard, Lyon 69008, France.
- 700 1_
- $a Couturier, J $u Unité de Génétique Somatique et Cytogénétique, Institut Curie, Paris Cedex 05 75248, France.
- 700 1_
- $a Erminio, G $u Epidemiology, Biostatistics and Committees Unit, Istituto Giannina Gaslini, Genova 16148, Italy.
- 700 1_
- $a Gambini, C $u Department of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy.
- 700 1_
- $a Garaventa, A $u Department of Haematology-Oncology, Istituto Giannina Gaslini, Genova 16148, Italy.
- 700 1_
- $a Gross, N $u Pediatric Oncology Research Unit, Lausanne University Hospital (CHUV), Lausanne 1011, Switzerland.
- 700 1_
- $a Haupt, R $u Epidemiology, Biostatistics and Committees Unit, Istituto Giannina Gaslini, Genova 16148, Italy.
- 700 1_
- $a Kohler, J $u Department of Paediatric Oncology, Southampton General Hospital, Southampton S016 6YD, UK.
- 700 1_
- $a Jeison, M $u Cancer Cytogenetique and Molecular Cytogenetique Laboratory, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
- 700 1_
- $a Lunec, J $u Northern Institute for Cancer Research, Newcastle University, Newcastle NE2 4HH, UK.
- 700 1_
- $a Marques, B $u Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisbon 1649-016, Portugal.
- 700 1_
- $a Martinsson, T $u Department of Clinical Genetics, Göteborg University, Sahlgrenska University Hospital, Göteborg 413 45, Sweden.
- 700 1_
- $a Noguera, R $u Department of Pathology, Medical School of Valencia, University of Valencia, Valencia 46010, Spain.
- 700 1_
- $a Parodi, S $u Institute of Electronics, Computer and Telecommunication Engineering, National Research Council, Genova 16149, Italy.
- 700 1_
- $a Schleiermacher, G $u 1] INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Paris Cedex 05 75248, France [2] Département d'Oncologie Pédiatrique, Institut Curie, Paris Cedex 05 75248, France.
- 700 1_
- $a Tweddle, D A $u Northern Institute for Cancer Research, Newcastle University, Newcastle NE2 4HH, UK.
- 700 1_
- $a Valent, A $u Département de Biologie et de Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif 94800, France.
- 700 1_
- $a Van Roy, N $u Center for Medical Genetics, Ghent University Hospital, Ghent 9000, Belgium.
- 700 1_
- $a Vicha, A $u Department of Paediatric Haematology and Oncology, Charles University and University Hospital Motol, Prague 15008, Czech Republic.
- 700 1_
- $a Villamon, E $u Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia 46009, Spain.
- 700 1_
- $a Tonini, G P $u Laboratory of Neuroblastoma, Onco/Haematology Laboratory, University of Padua, Pediatric Research Institute (IRP)-Città della Speranza, Corso Stati Uniti 4, Padova 35127, Italy.
- 773 0_
- $w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 112, č. 2 (2015), s. 290-5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25356804 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150424103939 $b ABA008
- 999 __
- $a ok $b bmc $g 1071596 $s 896893
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 112 $c 2 $d 290-5 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
- LZP __
- $a Pubmed-20150420
